Literature DB >> 9222252

Ocular neuromyotonia in a patient with cavernous sinus thrombosis secondary to mucormycosis.

A R Harrison1, J D Wirtschafter.   

Abstract

PURPOSE: To report a case of ocular neuromyotonia occurring after cavernous sinus thrombosis secondary to mucormycosis.
METHODS: Case report. We performed serial comprehensive neuro-ophthalmologic examinations.
RESULTS: Fifteen months after initial total ophthalmoplegia of the right eye and complete right upper eyelid ptosis, isolated ocular neuromyotonia, characterized by episodic upward jerking movements of the right upper eyelid, was noted.
CONCLUSION: Ocular neuromyotonia, which usually manifests in patients with a history of intracranial tumors and cranial radiation, may also be secondary to infectious cavernous sinus thrombosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9222252     DOI: 10.1016/s0002-9394(14)71663-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

1.  Ocular neuromyotonia with both tonic and paroxysmal components due to vascular compression.

Authors:  Maurizio Versino; Silvia Colnaghi; Alessandra Todeschini; Elisa Candeloro; Sabrina Ravaglia; Arrigo Moglia; Vittorio Cosi
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

2.  Strabismus Surgery in Patients With Ocular Neuromyotonia: Potential Unmasking of the Condition and Effective Management Tool.

Authors:  J Anna Kim; Federico G Velez; Stacy L Pineles
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

3.  Acquired neuromyotonia following upper respiratory tract infection: a case report.

Authors:  Ibrahim Imam; Simon Edwards; C Oliver Hanemann
Journal:  Cases J       Date:  2009-09-08

4.  Infection-Associated Peripheral Nerve Hyperexcitability: An Under-Recognized Entity.

Authors:  Ajith Sivadasan; Aditya Nair; Angel Miraclin; Arun Mathai Mani; A T Prabhakar; John Antony Jude Prakash; Vivek Mathew
Journal:  Ann Indian Acad Neurol       Date:  2021-04-28       Impact factor: 1.383

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.